"The 19 drug companies that have imposed restrictions on safety-net hospital access to 340B drug pricing program discounts collectively brought more than $660 billion in revenues in 2021. The banner year for the companies occurred as hospitals reported increasing losses of 340B savings from the...
"A federal court has ruled it’s up to the HHS to determine how to repay hospitals enrolled in the 340B drug discount program after years of underpayments, sparking concern from hospital groups. The court’s ruling on Tuesday is the latest update in a yearslong legal dispute...
"The House of Representatives Dec. 23 passed an amended version of the $1.7 trillion omnibus appropriations bill that funds the federal government through the end of the current fiscal year. The Senate passed the bill Dec. 22. Congress also passed another short-term continuing resolution through...
"Seventeen drug companies, including some of the world’s largest, are flouting a 30-year-old federal program that supports hospitals serving patients with low incomes and those who live in rural communities. Both the Trump and Biden administrations have deemed these actions unlawful. But these drugmakers continue to ignore the law,...
"This spring, I find myself embracing the change of season and reflecting on the challenges of seasons past. For two years, we intensive-care professionals have cared for critically ill COVID-19 patients with ravaged lungs who clung for life on ventilators. We witnessed tragic and heartbreaking...
"President Biden’s call during his State of the Union address for Congress to pass legislation to control drug prices provides a good opportunity to note a law that already is on the books that helps curb drugmakers’ price hikes. As lawmakers prepare to debate the...
"A late 2021 survey of hospitals participating in the 340B drug pricing program suggests pharma industry leaders’ recent restrictions on drug discounts are costing safety net hospitals hundreds of thousands to millions of dollars in savings. 340B Health, an industry group representing these hospitals, said critical...
"The main lobbying association for drug makers, the Pharmaceutical Research and Manufacturers of America, spent a record $28.9 million on lobbying last year as it pushed back on legislation meant to control the price of medicine. The trade group asked lawmakers instead to create an out-of-pocket...
"The hospital industry pushed back on the findings, the latest salvo in an ongoing battle over the program, which provider trade groups like the American Hospital Association and America's Essential Hospitals argue is essential to preserving the financial stability of safety net facilities and their...
The 340B drug pricing program may discourage drug manufacturers from raising prices and instead may have the effect of reducing list prices for certain drugs. That’s according to a new study published in the Journal of the American Medical Association (JAMA). Study authors Sean Dickson of West Health and Ian...
